Vitrakvi

Vitrakvi (larotrectinib) is an oral therapy for solid tumors with NTRK gene fusions. This targeted treatment blocks cancer cell growth by inhibiting TRK proteins. Vitrakvi is prescribed after genetic testing confirms NTRK fusion status.

Vitrakvi is used to treat adults and children with solid tumors that have spread or cannot be removed by surgery. It is prescribed when cancer cells contain an NTRK gene fusion. This targeted therapy works by blocking proteins that help cancer grow. Vitrakvi is often used for rare or advanced cancers that have not responded to other treatments.

Vitrakvi may help slow or stop the growth of cancer cells in people with NTRK gene fusions. Some patients experience tumor shrinkage or stabilization of disease. Effects vary by individual and cancer type. Regular monitoring by a healthcare provider is recommended to assess response.

Vitrakvi should be taken exactly as prescribed by a doctor. Keep all appointments for blood tests and imaging to monitor progress. Inform your healthcare provider about all medications and supplements you take. Avoid starting new treatments without consulting your doctor first.

Larotrectinib may interact with strong CYP3A inhibitors or inducers, altering its effectiveness. Grapefruit products can increase larotrectinib levels in the blood. Certain other medications, including some antibiotics and antifungals, may also interact. Always discuss your full medication list with your doctor.